{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:14:14Z","timestamp":1769264054408,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioma is the most common primary brain tumor of the central nervous system and is associated with poor clinical outcomes, particularly in high\u2010grade diease. The immune checkpoint protein B7\u2010H3 (CD276) is significantly overexpressed in glioma and multiple other solid tumors, highlighting its potential as a diagnostic biomarker and therapeutic target. However, the availability of high\u2010performance antibodies suitable for clinic in vitro diagnosis (IVD) applications remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to develop a novel rabbit monoclonal antibody (clone 36H7) targeting human B7\u2010H3, and to evaluate its suitability for clinical diagnostic use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Rabbits were immunized with recombinant human B7\u2010H3 protein, followed by monoclonal antibody generation and systematic screening. The resulting antibody was assessed for specificity, affinity and stability. Its performance was validated through Western blot, ELISA, surface plasmon resonance (SPR), flow cytometry, immunofluorescence, and immunohistochemistry (IHC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clone 36H7 demonstrated high specificity and robust stability across multiple assay platforms. In IHC analysis of glioma samples (n = 206), B7\u2010H3 positivity was detected in 97% of cases. In addition, B7\u2010H3 expression was observed in 85.4% of vascular endothelial cells, supporting its strong detection capability in tumor\u2010associated compartments. Tonsil tissue was established as a reliable quality control material to ensure assay consistency and reproducibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The rabbit monoclonal antibody 36H7 exhibits excellent specificity, stability and board applicability across analytical platforams, meeting key requirments for clinical diagnostic development targeting B7\u2010H3 in glioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1736583","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:43Z","timestamp":1769150863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and characterization of a novel B7-H3 rabbit monoclonal antibody for glioma diagnosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[{"name":"Chongqing University Fuling Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Wang","sequence":"additional","affiliation":[{"name":"T-Maximum Pharmaceutical, Co., Ltd","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wen","sequence":"additional","affiliation":[{"name":"T-Maximum Pharmaceutical, Co., Ltd","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghsuen","family":"Chiu","sequence":"additional","affiliation":[{"name":"T-Maximum Pharmaceutical, Inc.","place":["Delaware, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Jia","sequence":"additional","affiliation":[{"name":"T- Maximum Pharmaceutical, Co. Ltd","place":["Ningbo, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijin","family":"Li","sequence":"additional","affiliation":[{"name":"T-Maximum Pharmaceutical, Inc.","place":["Delaware, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Shang","sequence":"additional","affiliation":[{"name":"T-Maximum Pharmaceutical, Co., Ltd","place":["Chongqing, China"]},{"name":"Chongqing International Institute for Immunology","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12253-017-0220-8","article-title":"Reproducibility and prognostic potential of Ki-67 proliferation index when comparing digital-image analysis with standard semi-quantitative evaluation in breast cancer","volume":"24","author":"\u00c1cs","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5114\/wo.2022.113502","article-title":"Soluble B7-H3 level in breast cancer and its relationship with clinicopathological variables and T cell infiltration","volume":"26","author":"Avci","year":"2022","journal-title":"Contemp. Oncol. Pozn."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B5","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"104077","DOI":"10.1016\/j.cellimm.2020.104077","article-title":"B7-H3: a promising therapeutic target for autoimmune diseases","volume":"352","author":"Chen","year":"2020","journal-title":"Cell. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2767-9764.CRC-22-0420","article-title":"A phase I trial of VEGF-A inhibition combined with PD-L1 blockade for recurrent glioblastoma","volume":"3","author":"Chiu","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.wneu.2019.10.044","article-title":"Expression and clinical significance of immune checkpoint regulator B7-H3 (CD276), an immune checkpoint protein, in human meningioma","volume":"135","author":"Deng","year":"2020","journal-title":"World Neurosurg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Investig. New Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.21037\/jgo-21-821","article-title":"A three-phase trans-ethnic study reveals B7-H3 expression is a significant and independent biomarker associated with Colon cancer overall survival","volume":"12","author":"Gao","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276), an immune checkpoint protein, research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.7150\/ijbs.85813","article-title":"B7-H3 in brain malignancies: immunology and immunotherapy","volume":"19","author":"Guo","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12026-019-09084-w","article-title":"B7-H3 modulates endothelial cell angiogenesis through the VEGF cytokine","volume":"67","author":"Lai","year":"2019","journal-title":"Immunol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","article-title":"B7-H3-targeted CAR-T cell therapy for solid tumors","volume":"41","author":"Li","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111926","DOI":"10.1016\/j.intimp.2024.111926","article-title":"Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration","volume":"132","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.semcancer.2023.03.006","article-title":"Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma","volume":"91","author":"Luo","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-09-0996","article-title":"Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38","volume":"9","author":"Luther","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/pin.13028","article-title":"Expression status of PD-L1 and B7-H3 in mesothelioma","volume":"70","author":"Matsumura","year":"2020","journal-title":"Pathol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e78885","DOI":"10.1371\/journal.pone.0078885","article-title":"Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues","volume":"8","author":"Mesri","year":"2013","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jocn.2019.08.044","article-title":"Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: a subset analysis of the CABARET trial","volume":"70","author":"Olafson","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2174\/1871527322666230406094257","article-title":"Immunotherapy for pediatric gliomas: CAR-T cells against B7-H3: a review of the literature","volume":"23","author":"Santiago-Vicente","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.ctro.2024.100849","article-title":"Systemic inflammatory markers and volume of enhancing tissue on post-contrast T1w MRI images in differentiating true tumor progression from pseudoprogression in high-grade glioma","volume":"49","author":"Satragno","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-019-00819-y","article-title":"T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting","volume":"38","author":"Sun","year":"2020","journal-title":"Investig. New Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2805576","DOI":"10.1155\/2021\/2805576","article-title":"ELK1 promotes epithelial-mesenchymal transition and the progression of lung adenocarcinoma by upregulating B7-H3","volume":"2021","author":"Yu","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/brainsci15020212","article-title":"Prognostic biomarkers in isocitrate dehydrogenase wild-type glioblastoma: a focus on B7-H3","volume":"15","author":"Y\u00fcceer","year":"2025","journal-title":"Brain Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41374-019-0238-5","article-title":"B7-H3 regulates differentiation and serves as a potential biomarker and Theranostic target for human glioblastoma","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab. Investig."},{"key":"B30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11060-024-04855-4","article-title":"Expression features of targets for anti-glioma CAR-T cell immunotherapy","volume":"171","author":"Zhang","year":"2024","journal-title":"J. Neurooncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"819236","DOI":"10.3389\/fcell.2022.819236","article-title":"Clinical significance of the expression of Co-Stimulatory molecule B7-H3 in papillary thyroid carcinoma","volume":"10","author":"Zhao","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J. Neurooncol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:45Z","timestamp":1769150865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1736583"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1736583","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1736583"}}